New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:26 EDTICPT, GEVALeerink reiterates caution on Intercept ahead of FLINT data
Leerink says the physicians it spoke to at its Healthcare Insights Conference who treat liver diseases were cautious on Intercept's (ICPT) obeticholic acid's clinical potential in non-alcoholic steatohepatitis due to its effect on LDL-C. Leerink remains cautious on the stock ahead of full FLINT data in the second half of 2014, as it believes there is as much if not more downside than upside due to safety concerns. The firm adds the specialists noted that they have screened and not found any patients that warrant treatment with an expensive enzyme replacement therapy, such as Synageva's (GEVA) sebelipase alfa.
News For ICPT;GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:26 EDTICPTIntercept price target lowered to $475 from $693 at Citigroup
Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCA’s cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.
December 18, 2014
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
07:10 EDTGEVASynageva announces active IND for SBC-103
Synageva BioPharma announced that the investigational new drug, or IND, application to the FDA to evaluate SBC-103 as a treatment for mucopolysaccharidosis IIIB, also known as Sanfilippo B syndrome, is active. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data from this study in 2015. The company recently completed a study assessing the integrity of the blood-brain barrier and other disease abnormalities in patients with MPS IIIB and plans to report data during the first quarter of 2015. The company is also conducting natural history studies in MPS IIIB. These include a retrospective natural history study of deceased MPS IIIB patients that began in July 2013 and a prospective, longitudinal natural history study in living MPS IIIB patients that began in September 2014.
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use